RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

Here's the full text version of the Deadwyler sleep deprivation primate paper -

http://biology.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pbio.0030299


Concerning Durect again, I should have added that they'll have approx $90 mil in cash at year end (having wisely used their recent runup to raise some additional money). Also, concerning their Sufentanil transdermal patch product, it is 1/5th the size of Duragesic (important since these patches tend to irritate the skin, and a new site is needed for each new patch (cancer patients and patients with long term pain often use these patches for months on end). Even more importantly, Durect's Sufentanil lasts for 7 days vrs only 3 days for Duragesic. It's amazing that investors assume they need a company with a new cancer drug to have a blockbuster, when something like Duragesic sells over $2 Bil/year.